Literature DB >> 29260298

Screening of chemical compound libraries identified new anti-Toxoplasma gondii agents.

Oluyomi Stephen Adeyemi1,2, Tatsuki Sugi1, Yongmei Han1, Kentaro Kato3.   

Abstract

Toxoplasma gondii is the etiological agent of toxoplasmosis, a common parasitic disease that affects nearly one-third of the human population. The primary infection can be asymptomatic in healthy individuals but may prove fatal in immunocompromised individuals. Available treatment options for toxoplasmosis patients are limited, underscoring the urgent need to identify and develop new therapies. Non-biased screening of libraries of chemical compounds including the repurposing of well-characterized compounds is emerging as viable approach to achieving this goal. In the present investigation, we screened libraries of natural product and FDA-approved compounds to identify those that inhibited T. gondii growth. We identified 32 new compounds that potently inhibit T. gondii growth. Our findings are new and promising, and further strengthen the prospects of drug repurposing as well as the screening of a wide range of chemical compounds as a viable source of alternative anti-parasitic therapeutic agents.

Entities:  

Keywords:  Anti-parasitic; Drug discovery; FDA-approved compounds; Natural products; Toxoplasmosis

Mesh:

Substances:

Year:  2017        PMID: 29260298     DOI: 10.1007/s00436-017-5698-1

Source DB:  PubMed          Journal:  Parasitol Res        ISSN: 0932-0113            Impact factor:   2.289


  15 in total

Review 1.  Lytic cycle of Toxoplasma gondii.

Authors:  M W Black; J C Boothroyd
Journal:  Microbiol Mol Biol Rev       Date:  2000-09       Impact factor: 11.056

Review 2.  Molecular approaches to diversity of populations of apicomplexan parasites.

Authors:  Hans-Peter Beck; Damer Blake; Marie-Laure Dardé; Ingrid Felger; Susana Pedraza-Díaz; Javier Regidor-Cerrillo; Mercedes Gómez-Bautista; Luis Miguel Ortega-Mora; Lorenza Putignani; Brian Shiels; Andrew Tait; Willie Weir
Journal:  Int J Parasitol       Date:  2008-10-21       Impact factor: 3.981

3.  New Imidazole-Based Compounds Active Against Trypanosoma cruzi.

Authors:  Oluyomi Stephen Adeyemi; María Teresa Molina; Abiodun Omokehinde Eseola; Cristina Fonseca-Berzal; Alicia Gómez-Barrio
Journal:  Comb Chem High Throughput Screen       Date:  2017       Impact factor: 1.339

4.  Microplate assay for screening Toxoplasma gondii bradyzoite differentiation with DUAL luciferase assay.

Authors:  Tatsuki Sugi; Tatsunori Masatani; Fumi Murakoshi; Shin-ichiro Kawazu; Kentaro Kato
Journal:  Anal Biochem       Date:  2014-06-30       Impact factor: 3.365

Review 5.  Biology and epidemiology of Toxoplasma gondii in man and animals.

Authors:  Dolores E Hill; Sreekumar Chirukandoth; J P Dubey
Journal:  Anim Health Res Rev       Date:  2005-06       Impact factor: 2.615

6.  Effects of dextran sulfates on the acute infection and growth stages of Toxoplasma gondii.

Authors:  Akiko Ishiwa; Kyousuke Kobayashi; Hitoshi Takemae; Tatsuki Sugi; Haiyan Gong; Frances C Recuenco; Fumi Murakoshi; Atsuko Inomata; Taisuke Horimoto; Kentaro Kato
Journal:  Parasitol Res       Date:  2013-10-06       Impact factor: 2.289

Review 7.  Acquired QT interval prolongation and HERG: implications for drug discovery and development.

Authors:  Keith Finlayson; Harry J Witchel; James McCulloch; John Sharkey
Journal:  Eur J Pharmacol       Date:  2004-10-01       Impact factor: 4.432

8.  Drug Repurposing Screening Identifies Novel Compounds That Effectively Inhibit Toxoplasma gondii Growth.

Authors:  Ashley J Dittmar; Allison A Drozda; Ira J Blader
Journal:  mSphere       Date:  2016-03-02       Impact factor: 4.389

9.  Inorganic nanoparticles kill Toxoplasma gondii via changes in redox status and mitochondrial membrane potential.

Authors:  Oluyomi Stephen Adeyemi; Yuho Murata; Tatsuki Sugi; Kentaro Kato
Journal:  Int J Nanomedicine       Date:  2017-02-28

Review 10.  Pharmacological effects of rutaecarpine as a cardiovascular protective agent.

Authors:  Sujie Jia; Changping Hu
Journal:  Molecules       Date:  2010-03-15       Impact factor: 4.411

View more
  9 in total

Review 1.  Epidemiology, Pathophysiology, Diagnosis, and Management of Cerebral Toxoplasmosis.

Authors:  Hany M Elsheikha; Christina M Marra; Xing-Quan Zhu
Journal:  Clin Microbiol Rev       Date:  2020-11-25       Impact factor: 26.132

2.  Interaction of apigenin-7-O-glucoside with pyrimethamine against Toxoplasma gondii growth.

Authors:  Daniel A Abugri; William H Witola
Journal:  J Parasit Dis       Date:  2019-12-02

3.  Evaluation of Current and Emerging Antimalarial Medicines for Inhibition of Toxoplasma gondii Growth in Vitro.

Authors:  Joshua B Radke; Jeremy N Burrows; Daniel E Goldberg; L David Sibley
Journal:  ACS Infect Dis       Date:  2018-07-25       Impact factor: 5.084

Review 4.  Protozoan persister-like cells and drug treatment failure.

Authors:  Michael P Barrett; Dennis E Kyle; L David Sibley; Joshua B Radke; Rick L Tarleton
Journal:  Nat Rev Microbiol       Date:  2019-08-23       Impact factor: 60.633

5.  Screening of compound libraries for inhibitors of Toxoplasma growth and invasion.

Authors:  Yongmei Han; Oluyomi Stephen Adeyemi; Mohammad Hazzaz Bin Kabir; Kentaro Kato
Journal:  Parasitol Res       Date:  2020-04-01       Impact factor: 2.289

6.  Two old drugs, NVP-AEW541 and GSK-J4, repurposed against the Toxoplasma gondii RH strain.

Authors:  Shuxian Liu; Mimi Wu; Qianqian Hua; Daiqiang Lu; Yuan Tian; Helin Yu; Linyan Cheng; Yinqi Chen; Jiaxin Cao; Xin Hu; Feng Tan
Journal:  Parasit Vectors       Date:  2020-05-11       Impact factor: 3.876

7.  In Vitro Screening to Identify Anti-Toxoplasma Compounds and In Silico Modeling for Bioactivities and Toxicity.

Authors:  Oluyomi Stephen Adeyemi; Olubunmi Atolani; Oluwakemi Josephine Awakan; Tomilola Debby Olaolu; Charles Obiora Nwonuma; Omokolade Alejolowo; David Adeiza Otohinoyi; Damilare Rotimi; Akinyomade Owolabi; Gaber El-Saber Batiha
Journal:  Yale J Biol Med       Date:  2019-09-20

Review 8.  Treatment of toxoplasmosis: Current options and future perspectives.

Authors:  Neda Konstantinovic; Hélène Guegan; Tijana Stäjner; Sorya Belaz; Florence Robert-Gangneux
Journal:  Food Waterborne Parasitol       Date:  2019-04-01

9.  Determination of lumefantrine as an effective drug against Toxoplasma gondii infection - in vitro and in vivo study.

Authors:  Dawei Wang; Mengen Xing; Saeed El-Ashram; Yingying Ding; Xiao Zhang; Xiaoyu Sang; Ying Feng; Ran Chen; Xinyi Wang; Ning Jiang; Qijun Chen; Na Yang
Journal:  Parasitology       Date:  2020-10-22       Impact factor: 3.234

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.